Skip to main content

Table 1 Baseline patient characteristics

From: Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study

Parameter 1) No. of patients (categorized data) or mean ± SD (qualitative data)
Age at insulin initiation, years [N = 511] 62.2 ± 10.0
Gender [N = 511]  
  Male 326 (63.8%)
  Female 185 (36.2%)
Duration of diabetes, years [N = 504] 11.8 ± 8.8
Duration of diabetes category [N = 504]  
  <5 years 99 (19.6%)
  ≥5, <10 years 125 (24.8%)
  ≥10, <15 years 134 (26.6%)
  ≥15 years 146 (29.0%)
HbA1c (%) [N = 506] 10.3 ± 2.0
HbA1c category [N = 506]  
  ≤8.0% 57 (11.3%)
  >8.0%, ≤10.0% 197 (38.9%)
  >10.0%, ≤12.0% 169 (33.4%)
  >12.0% 83 (16.4%)
FPG (mg/dL) [N = 254] 217.3 ± 80.8
PPG (mg/dL) [N = 329] 296.1 ± 96.0
BMI (kg/m2) [N = 490] 23.9 ± 4.0
Insulin regimen  
  Basal 32 (6.3%)
  Basal + short-acting 134 (26.2%)
  Short-acting 130 (25.4%)
  Premix 188 (36.8%)
  Other 27 (5.3%)
Microvascular diabetic complication [N = 505] 421 (83.4%)
  Nephropathy [N = 500] 304 (60.8%)
   Microalbuminuria [N = 498] 178 (35.7%)
   Macroalbuminuria [N = 505] 185 (36.6%)
   Renal failure [N = 509] 78 (15.3%)
  Retinopathy [N = 508] 209 (41.1%)
  Peripheral neuropathy [N = 509] 265 (52.1%)
  Foot ulcer [N = 510] 7 (1.4%)
Macrovascular disease [N = 510] 128 (25.1%)
  1. Abbreviations: BMI body mass index, FPG fasting plasma glucose, PPG postprandial plasma glucose.
  2. 1)Data are missing for some patients; numbers with available data are shown in parentheses.